专利视角下全球钠-葡萄糖共转运蛋白2抑制剂研究现状分析  

Research Progress Analysis on the Sodium-glucose Co-transporter 2 Inhibitors from the Perspective of Global Patent

作　　者：金鑫[1] 付尧[2] 张艳莉[1] JIN Xin;FU Yao;ZHANG Yanli(Jilin University,Changchun 130021,China;Department of Critical Care Medicine,The First Hospital of Jilin University,Changchun 130021,China)

机构地区：[1]吉林大学,长春130021 [2]吉林大学第一医院重症医学科,长春130021

出　　处：《中国现代应用药学》2023年第7期976-981,共6页Chinese Journal of Modern Applied Pharmacy

摘　　要：目的梳理全球钠-葡萄糖共转运蛋白2(sodium-glucoseco-transporter,SGLT2)抑制剂相关专利的现状,探讨该领域技术的研究布局及发展趋势,为国内同行提供参考借鉴。方法以全球SGLT2抑制剂相关专利为研究对象,通过Incopat数据平台对其进行计量学统计和分析。结果与结论SGLT2抑制剂相关技术专利于2014年后开始迅速增加,现已进入平稳发展阶段。分类号A61K、A61P、C07D的专利申请相对活跃,全球热点主题分布在医用配置、化合物或药物制剂的特定治疗活性等方向,头部研发机构主要聚焦在关键中间体、半水合物、协同转运蛋白、心力衰竭等聚类关键词方面。OBJECTIVE To comb the current status of patents related to sodium-glucose co-transporter(SGLT2)in the world,and explore the research layout and development trend,to provide reference for domestic peers.METHODS Took the global SGLT-2 patents as the research object,and conduct metrological statistics and analysis based on the Incopat patent data.RESULTS&CONCLUSION SGLT2 inhibitor patents began to increase rapidly since 2014,and entered a steady stage now.A61K,A61P,C07D patent applications were relatively active,global topics were distributed in the direction of medical configuration,specific therapeutic activity of compounds or pharmaceutical preparations,etc.The head R&D institutions mainly focused on key intermediates,hemihydrate,cotransporters,heart failure and other clustering keywords.

关 键 词：钠-葡萄糖共转运蛋白2 抑制剂 专利布局 专利分析 

分 类 号：R977.15[医药卫生—药品]